Plus therapeutics showcases leptomeningeal metastases programs at 2024 sno/asco conference

Austin, texas, july 25, 2024 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (“plus” or the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, will have multiple opportunities to present data at the 2024 society for neuro-oncology (sno) / american society for clinical oncology (asco) cns metastases conference august 8-10, in denver, colorado. “this year's sno/asco metastases conference is a key opportunity for plus to highlight advancements in our lm therapeutics and diagnostics programs,” said marc h.
pstv Ratings Summary
pstv Quant Ranking